Cargando…

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease

Treatment of Chagas disease with nifurtimox requires age‐ and body weight‐adjusted dosing, resulting in complex dosing instructions. Appropriate formulations are needed for precise and compliant dosing, especially in pediatric patients. We characterized the biopharmaceutical features of a standard n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stass, Heino, Feleder, Ethel, Garcia‐Bournissen, Facundo, Nagelschmitz, Johannes, Weimann, Boris, Yerino, Gustavo, Altcheh, Jaime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246722/ https://www.ncbi.nlm.nih.gov/pubmed/33029953 http://dx.doi.org/10.1002/cpdd.871

Ejemplares similares

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
por: Moroni, Samanta, et al.
Publicado: (2019)

Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox
por: Lang, Dieter, et al.
Publicado: (2022)

Correction to “Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox”
por: Lang, Dieter, et al.
Publicado: (2023)

Prevention of congenital Chagas through treatment of girls and women of childbearing age
por: Moscatelli, Guillermo, et al.
Publicado: (2015)

Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults
por: Falk, N., et al.
Publicado: (2022)

ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment
por: Rivero, Rocio, et al.
Publicado: (2023)

Longitudinal follow up of serological response in children treated for Chagas disease
por: Moscatelli, Guillermo, et al.
Publicado: (2019)

In vivo Metabolism of Nifurtimox and the Drug-Drug Interaction Potential Including its Major Metabolites
por: Schulz, Simone I., et al.
Publicado: (2023)

Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)
por: Altcheh, Jaime, et al.
Publicado: (2023)

Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole
por: Ruiz-Lancheros, Elizabeth, et al.
Publicado: (2018)

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
por: Forsyth, Colin J., et al.
Publicado: (2016)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016)

Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy despite Lower Plasma Concentrations than in Adults
por: Altcheh, Jaime, et al.
Publicado: (2014)

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment
por: Santamaria, Cynthia, et al.
Publicado: (2014)

Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults
por: Olivera, Mario Javier, et al.
Publicado: (2015)

Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox
por: Vergara, Camilo, et al.
Publicado: (2019)

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
por: Altcheh, Jaime, et al.
Publicado: (2021)

Urban Chagas disease in children and women in primary care centres in Buenos Aires, Argentina
por: Moscatelli, Guillermo, et al.
Publicado: (2015)

Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study
por: González, Nicolás Leonel, et al.
Publicado: (2022)

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment
por: Jackson, Yves, et al.
Publicado: (2013)

Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study
por: Stass, Heino, et al.
Publicado: (2013)

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina
por: Vizcaya, David, et al.
Publicado: (2021)

Optimization and biological validation of an in vitro assay using the transfected Dm28c/pLacZ Trypanosoma cruzi strain
por: Gulin, Julián Ernesto Nicolás, et al.
Publicado: (2021)

Quality of Reporting and Adherence to ARRIVE Guidelines in Animal Studies for Chagas Disease Preclinical Drug Research: A Systematic Review
por: Gulin, Julián Ernesto Nicolás, et al.
Publicado: (2015)

Abdominal Cystic Echinococcosis Treated with Albendazole. A Pediatric Cohort Study
por: Moroni, Samanta, et al.
Publicado: (2016)

Nifurtimox Inhibits the Progression of Neuroblastoma in vivo
por: Kong, Eryan, et al.
Publicado: (2019)

Miltefosine and Benznidazole Combination Improve Anti-Trypanosoma cruzi In Vitro and In Vivo Efficacy
por: Gulin, Julián Ernesto Nicolás, et al.
Publicado: (2022)

Quantification of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up
por: Muñoz, Gabriela, et al.
Publicado: (2019)

Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia
por: Bianchi, Fiorella, et al.
Publicado: (2015)

2128. Lack of Congenital Transmission in Infants Born of Female Patients with Chagas Disease who Became Pregnant During a Nifurtimox Study (CHICO and CHICO SECURE Study)
por: Jaime, A L T C H E H, et al.
Publicado: (2022)

Benznidazole Treatment of Chagasic Encephalitis in Pregnant Woman with AIDS
por: Bisio, Margarita, et al.
Publicado: (2013)

Evaluation of the Chagas Western Blot IgG Assay for the Diagnosis of Chagas Disease
por: Brossas, Jean-Yves, et al.
Publicado: (2021)

Congenital syphilis in Argentina: Experience in a pediatric hospital
por: Garcia, Luciana Noemí, et al.
Publicado: (2021)

Development of an Age-Appropriate Mini Orally Disintegrating Carvedilol Tablet with Paediatric Biopharmaceutical Considerations
por: Khan, Dilawar, et al.
Publicado: (2021)

Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021
por: Abbott, Andrew, et al.
Publicado: (2022)

Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole
por: Buschini, Annamaria, et al.
Publicado: (2009)

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine
por: Du, Michael, et al.
Publicado: (2016)

720. Efficacy of Nifurtimox + Eflornithine in the Treatment of African Trypanosomiasis. Systematic Review
por: Hidalgo, Jessica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r2edpgenvt9hg1al0ojqfp2hgp